Back to Search
Start Over
Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model.
- Source :
-
Transplant immunology [Transpl Immunol] 2018 Feb; Vol. 46, pp. 14-20. Date of Electronic Publication: 2017 Oct 05. - Publication Year :
- 2018
-
Abstract
- Background: Janus kinase (JAK) inhibitors are thought to be promising candidates to aid renal transplantation. However, the effectiveness of JAK inhibitors against features of chronic rejection, including interstitial fibrosis/tubular atrophy (IF/TA) and glomerulosclerosis, has not been elucidated. Here, we investigated the effect of AS2553627, a novel JAK inhibitor, on the development of chronic rejection in rat renal transplantation.<br />Methods: Lewis (LEW) to Brown Norway (BN) rat renal transplantation was performed. Tacrolimus (TAC) at 0.1mg/kg was administered intramuscularly once a day for 10 consecutive days starting on the day of transplantation (days 0 to 9) to prevent initial acute rejection. After discontinuation of TAC treatment from days 10 to 28, AS2553627 (1 and 10mg/kg) was orally administered with TAC. At 13weeks after renal transplantation, grafts were harvested for histopathological and mRNA analysis. Creatinine and donor-specific antibodies were measured from plasma samples. Urinary protein and kidney injury markers were also evaluated.<br />Results: AS2553627 in combination with TAC exhibited low plasma creatinine and a marked decrease in urinary protein and kidney injury markers, such as tissue inhibitor of metalloproteinase-1 and kidney injury molecule-1. At 13weeks, histopathological analysis revealed that AS2553627 treatment inhibited glomerulosclerosis and IF/TA. In addition, upregulation of cell surface markers, fibrosis/epithelial-mesenchymal transition and inflammation-related genes were reduced by the combination of AS2553672 and TAC, particularly CD8 and IL-6 mRNAs, indicating that AS2553627 prevented cell infiltration and inflammation in renal allografts.<br />Conclusions: These results indicate the therapeutic potential of JAK inhibitors in chronic rejection progression, and suggest that AS2553627 is a promising agent to improve long-term graft survival after renal transplantation.<br /> (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Chronic Disease
Disease Models, Animal
Drug Therapy, Combination
Glomerulosclerosis, Focal Segmental immunology
Graft Rejection immunology
Humans
Interleukin-6 genetics
Interleukin-6 metabolism
Janus Kinases antagonists & inhibitors
Rats
Rats, Inbred Lew
Tacrolimus therapeutic use
Allografts immunology
Glomerulosclerosis, Focal Segmental prevention & control
Graft Rejection prevention & control
Kidney Transplantation
Piperidines therapeutic use
Pyrroles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1878-5492
- Volume :
- 46
- Database :
- MEDLINE
- Journal :
- Transplant immunology
- Publication Type :
- Academic Journal
- Accession number :
- 28988984
- Full Text :
- https://doi.org/10.1016/j.trim.2017.10.001